Skip to content

Released Mar 26, 2026, after the close

10-K filed Mar 26, 2026, 85 days after period end · 0001193125-26-126192

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$12.57Mderived+24,080.8% vs Q4 2024no prior Q3 2025 on file
Net Income$31.52MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$31,405,000N/M
Operating Cash Flowderived-$8,351,000N/M
Margins · derived
Operating margin249.8%+42028.6 pt vs Q4 2024
Net margin250.7%+40419.9 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$12.57M$52.00K$223.00K$278.00K
Net Income$31.52M-$20.89M$51.21M$26.79M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR